Scholars Central

Conference abstract

Current global challenges in the Bioequivalence of CR/MR and Multiphasic formulations of drugs

Authors: Murray P. Ducharme

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

M odifi ed release products are becoming more and more sophisticated in their design and release, prompting a careful scientifi c re-evaluation of what pharmacokinetic metrics and statistical tests are needed to make sure that generic products are truly equivalent to their reference counterparts, while ensuring that additional evaluations or tests are not required needlessly. It is therefore crucial that regulatory requirements are scientifi cally sound to protect the public, while allowing access to generic products once market exclusivity and patent protection have elapsed. Th is presentation will be broken up in three parts. A summary of the current requirements from US FDA, Health Canada and EMA will fi rst be reviewed for the diff erent classes of modifi ed release products available. A critical evaluation of these requirements will follow. Case examples will be presented to highlight certain points. Finally, specifi c scientifi c recommendations will be proposed in order to stimulate further discussion and debate on this topic from a global harmonization perspective

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioequivalence & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Murray P. Ducharme”